Loading
Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval.
Luca Gianni led medical oncology at the Istituto Nazionale dei Tumori and then at San Raffaele Hospital in Milan, and now leads the Fondazione Michelangelo. He was first author of the 2012 Lancet Oncology report of NeoSphere, the phase 2 trial in which pertuzumab plus trastuzumab and docetaxel produced a higher pathological complete response rate than trastuzumab and docetaxel, and of the NOAH trial of neoadjuvant trastuzumab. His trials helped establish pathological complete response as an endpoint for accelerated approval.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study Europe PMC author record matched by affiliation (Fondazione Michelangelo); 68 citations on Europe PMC. | Journal of Clinical Oncology | 2022 |
| Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma Europe PMC author record matched by affiliation (Fondazione Michelangelo); 50 citations on Europe PMC. | Cancer medicine | 2023 |
| Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab Europe PMC author record matched by affiliation (Fondazione Michelangelo); 30 citations on Europe PMC. | JNCI: Journal of the National Cancer Institute | 2022 |
One of the most cited papers Europe PMC returns for Luca Gianni at Fondazione Michelangelo, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Luca Gianni at Fondazione Michelangelo, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Luca Gianni at Fondazione Michelangelo, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares the tags breast, trialist.
Shares the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares the tags breast, trialist.
Shares the tags breast, trialist.